Condition: Non Small Cell Lung Cancer (Squamous or Non Squamous) · Stage 4 NSCLC · Sponsor: Eikon Therapeutics
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
This description comes directly from the study's public registry record.
Elelta Shiferraw · 314-209-3659 · shiferrawe@eikontx.com
Always discuss trial participation with your own doctor first.
| Southern Cancer Center, P.C. | Daphne, Alabama, United States | Recruiting |
| Los Angeles Cancer Network | Glendale, California, United States | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Pueblo, Colorado, United States | Recruiting |
| NYU Langone Hospital Long Island | Mineola, New York, United States | Recruiting |
| NYU Langone Hospital Manhattan | New York, New York, United States | Recruiting |
| White Plains Hospital | White Plains, New York, United States | Recruiting |
| Blue Ridge Cancer Center | Blacksburg, Virginia, United States | Recruiting |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | Recruiting |
| Shenandoah Oncology P.C. | Winchester, Virginia, United States | Recruiting |
| Institut Catala D'Oncologia de Girona | Girona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07365319